首页> 美国卫生研究院文献>other >Therapeutic Perspectives of Drugs Targeting Toll-Like Receptors Based on Immune Physiopathology Theory of Alzheimers Disease
【2h】

Therapeutic Perspectives of Drugs Targeting Toll-Like Receptors Based on Immune Physiopathology Theory of Alzheimers Disease

机译:基于阿尔茨海默氏病免疫生理病理学理论的靶向收费受体的药物的治疗前景

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Alzheimer's disease (AD) is a neurodegenerative disease associated with the development of dementia. It has been established that the pathological hallmarks of neurofibrillary tau protein tangles and senile β-amyloid protein plaques lead to degeneration of neurons via inflammatory pathways. The progressive death of neurons, primarily cholinergic, results in a gradual and fatal decline of cognitive abilities and memory. By targeting these pathological hallmarks and their associated pathways, AD drug therapy can potentially attenuate the disease state. In this review article, we focus on newly proposed and experimental AD drug treatment. We discuss three characteristic areas of AD treatment: prevention of neurotoxic β-amyloid protein plaque formation, stability of neuronal tau proteins, and increase in neuronal growth and function. The primary drug therapy methods and patents discussed include the use of neurotrophic factors and targeting of the amyloid precursor protein cleavage pathway as prevention of β-amyloid formation and tau aggregation.
机译:阿尔茨海默氏病(AD)是与痴呆症发展相关的神经退行性疾病。已经确定,神经原纤维tau蛋白缠结和老年性β-淀粉样蛋白斑块的病理学特征导致神经元通过炎症途径变性。神经元的逐步死亡,主要是胆碱能,导致认知能力和记忆力的逐渐和致命下降。通过针对这些病理特征及其相关途径,AD药物治疗可以潜在地减轻疾病状态。在这篇综述文章中,我们重点介绍新近提出的和实验性的AD药物治疗。我们讨论了AD治疗的三个特征领域:预防神经毒性β-淀粉样蛋白斑块的形成,神经元tau蛋白的稳定性以及神经元生长和功能的增加。讨论的主要药物治疗方法和专利包括使用神经营养因子和靶向淀粉样前体蛋白裂解途径,以预防β-淀粉样蛋白形成和tau聚集。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号